Table 5.
Proportion of Subjects with Reactive Point-of-Care HIV Test Results, by Fiebig Stage
| Fiebig stage | N | OraQuick Oral fluid n/N (%) | OraQuick Fingerstick n/N (%) | Uni-Golda n/N (%) | INSTIa n/N (%) | Determine Combo n/N (%) |
|---|---|---|---|---|---|---|
| I/II | 5 | 0/4 (0) | 0/5 (0) | 0/2 (0) | 0/2 (0) | 0/3 (0) |
| II | 1 | 0/1 (0) | 0/1 (0) | 0/1 (0) | — | 0/1 (0) |
| III | 4 | 0/3 (0) | 1/4 (25) | — | 1/2 (50) | 1/3 (33) |
| IV | 4 | 0/3 (0) | 2/4 (50) | 0/1 (0) | 2/2 (100) | 3/3 (100) |
| V | 17 | 9/17 (53) | 15/17 (88) | 11/11 (100) | 6/6 (100) | 16/16 (100) |
| VI | 10 | 9/10 (90) | 10/10 (100) | 9/9 (100) | 1/1 (100) | 7/7 (100) |
| Total | 41 | 18/38 (47) | 28/41 (68) | 20/24 (83) | 10/13 (77) | 27/33 (82) |
a
The study protocol switched from use of Uni-Gold (N = 24) to INSTI (N = 13) in Spring 2013.